AstraZeneca has completed all clinical studies required to support the first filings for the transition of its chronic ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket ... used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort, Breztri Aerosphere and Airsupra.

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Inhaled corticosteroids (ICS), short- and ... activity thought to result in alveolar enlargement seen in COPD, such as AstraZeneca's discovery-phase matrix metalloproteinase 12 (MMP12) inhibitor.

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.